AKRO - Deadline in 7 Days: Kessler Topaz Meltzer & Check LLP Reminds Investors of Deadline in Class Action Lawsuit Against Akero Therapeutics Inc. (AKRO) | Benzinga
RANDOR, Pa., June 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) on behalf of investors who purchased or acquired Akero common stock between September 13, 2022 and October 9, 2023, inclusive (the "Class Period").. The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Akero's materially misleading statements and omissions to the public, Akero's investors have suffered significant losses.
If you suffered Akero losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/akero-therapeutics-inc?utm_source=PR&utm_medium=link&utm_campaign=akro&mktm=r
You can also contact attorney Jonathan Naji, Esq. of Kessler Topaz by calling (484) 270-1453 or by email at info@ktmc.com. The lead plaintiff deadline is June 25, 2024.
DEFENDANTS' ALLEGED MISCONDUCT
Akero is a clinical stage drug development company which has yet to generate any revenues because the FDA has not approved any of its drug candidates for sale. To finance the company's operations, Akero conducted two secondary stock offerings and one at-the-market stock offering during the Class Period, raising over $577 million. In order to successfully complete these offerings and raise part of the funding, Akero needed to develop and commercialize EFX, Akero's lead product candidate, which was being developed to treat Nonalcoholic steatohepatitis ("NASH") - a serious form of nonalcoholic fatty liver disease that is estimated to affect 17 million Americans.
The Class Period begins on September 13, 2022. On that ...
AKRO)>Full story available on Benzinga.com